Linked Data API

Show Search Form

Search Results

1239272
unstar this property registered interest false remove filter
star this property date less than 2020-09-30more like thismore than 2020-09-30
star this property answering body
Foreign, Commonwealth and Development Office more like this
star this property answering dept id 208 more like this
star this property answering dept short name Foreign, Commonwealth and Development Office more like this
star this property answering dept sort name Foreign, Commonwealth and Development Office more like this
star this property hansard heading Development Aid: Maternal Mortality more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what changes have been made to UK Aid spending on reducing maternal deaths which satisfactorily address the amber/red ratings for impact, effectiveness, sustainability and value for money given by the Independent Commission for Aid Impact in 2018. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 97554 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2020-10-05more like thismore than 2020-10-05
star this property answer text <p>The Independent Commission for Aid Impact (ICAI) review of maternal health results in 2018 made five recommendations, including adopting a long-term approach to maternal health planning, linking strongly to health system strengthening work and increasing the focus on quality of care. We welcomed all recommendations and the 2020 follow up review acknowledged our swift progress, finding that the UK had 'enhanced its emphasis on the need for good quality, respectful care for women and their babies and increased focus on adolescents and poorer women within its new family planning programmes'. ICAI also recognised the UK Government's commitment to Ending the Preventable Deaths of Mothers, Newborns and Children by 2030 and to international advocacy for comprehensive sexual reproductive health and rights.</p><p>Using internationally accepted methods, we estimate that the UK Government has spent an average of approximately £1 billion per year on Maternal Newborn and Child Health between 2013/14 - 2017/18, on a range of bilateral and multilateral programmes. Maternal health remains a key priority throughout our health work, with recently announced investments including £600 million to the Reproductive Health Supplies programme to buy family planning supplies for millions more women and girls in the world's poorest countries each year.</p><p>The UK commitment to ending preventable deaths has created further momentum to ensure the right balance in the FCDO portfolio across family planning, health services and other essential interventions for maternal and newborn health and wellbeing. This holistic approach is essential if we are to maximise the impact of our money and policy, and more important than ever before given the challenges that the COVID-19 pandemic is creating for health services across the world. In responding to the ICAI recommendations, we are reviewing our approach to maternal health results to include more context based country data and to increase our focus on long-term, sustainable change.</p>
star this property answering member constituency Aldridge-Brownhills more like this
star this property answering member printed Wendy Morton more like this
unstar this property grouped question UIN 97555 more like this
star this property question first answered
less than 2020-10-05T16:08:22.343Zmore like thismore than 2020-10-05T16:08:22.343Z
star this property answering member
4358
star this property label Biography information for Wendy Morton more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
1239275
unstar this property registered interest false remove filter
star this property date less than 2020-09-30more like thismore than 2020-09-30
star this property answering body
Foreign, Commonwealth and Development Office more like this
star this property answering dept id 208 more like this
star this property answering dept short name Foreign, Commonwealth and Development Office more like this
star this property answering dept sort name Foreign, Commonwealth and Development Office more like this
star this property hansard heading Development Aid: Postnatal Care more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, with reference to the report by the Independent Commission for Aid Impact entitled Assessing DFID’s Results in Improving Maternal Health, published in October 2018, what methodology he is using to measure progress against the finding that DFID’s portfolio was not well balanced across family planning, health services and other interventions, so as to maximise medium-to-long-term-impact. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 97555 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2020-10-05more like thismore than 2020-10-05
star this property answer text <p>The Independent Commission for Aid Impact (ICAI) review of maternal health results in 2018 made five recommendations, including adopting a long-term approach to maternal health planning, linking strongly to health system strengthening work and increasing the focus on quality of care. We welcomed all recommendations and the 2020 follow up review acknowledged our swift progress, finding that the UK had 'enhanced its emphasis on the need for good quality, respectful care for women and their babies and increased focus on adolescents and poorer women within its new family planning programmes'. ICAI also recognised the UK Government's commitment to Ending the Preventable Deaths of Mothers, Newborns and Children by 2030 and to international advocacy for comprehensive sexual reproductive health and rights.</p><p>Using internationally accepted methods, we estimate that the UK Government has spent an average of approximately £1 billion per year on Maternal Newborn and Child Health between 2013/14 - 2017/18, on a range of bilateral and multilateral programmes. Maternal health remains a key priority throughout our health work, with recently announced investments including £600 million to the Reproductive Health Supplies programme to buy family planning supplies for millions more women and girls in the world's poorest countries each year.</p><p>The UK commitment to ending preventable deaths has created further momentum to ensure the right balance in the FCDO portfolio across family planning, health services and other essential interventions for maternal and newborn health and wellbeing. This holistic approach is essential if we are to maximise the impact of our money and policy, and more important than ever before given the challenges that the COVID-19 pandemic is creating for health services across the world. In responding to the ICAI recommendations, we are reviewing our approach to maternal health results to include more context based country data and to increase our focus on long-term, sustainable change.</p>
star this property answering member constituency Aldridge-Brownhills more like this
star this property answering member printed Wendy Morton more like this
unstar this property grouped question UIN 97554 more like this
star this property question first answered
less than 2020-10-05T16:08:22.393Zmore like thismore than 2020-10-05T16:08:22.393Z
star this property answering member
4358
star this property label Biography information for Wendy Morton more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
390468
unstar this property registered interest false remove filter
star this property date less than 2015-07-15more like thismore than 2015-07-15
star this property answering body
Department for Transport more like this
star this property answering dept id 27 more like this
star this property answering dept short name Transport more like this
star this property answering dept sort name Transport more like this
star this property hansard heading Large Goods Vehicles more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Transport, if his Department will make an assessment of whether the powers local councils and police have to enforce restrictions on heavy goods vehicles driving on weight-restricted roads are sufficient to protect rural roads and surrounding environments. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham more like this
star this property uin 7365 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
star this property answer text <p>All road users benefit from clear directions, including HGV drivers. It is clearly not in the interests of HGV drivers to rely upon inaccurate information, which may make them late or even involve them in accidents. Nevertheless, we believe that legislation would be a costly, bureaucratic and inappropriate way of dealing with the problem. Instead we have made significant efforts to link together freight associations, local authorities and satnav companies to ensure that HGV drivers are aware of the issue and have the latest information available to them.</p><p> </p><p> </p><p> </p><p>Councils already have the means to set height and weight restrictions for roads, which are enforced by the police, and HGV satnav devices increasingly include up-to-date routing information that takes account of such restrictions.</p><p> </p><p> </p><p> </p><p>Decisions on all aspects of traffic management policy are the responsibility of local traffic authorities, and how they and the police enforce this once they are in place it is a matter for them. We believe the necessary enforcement powers are available for this.</p><p> </p>
star this property answering member constituency Harrogate and Knaresborough more like this
star this property answering member printed Andrew Jones more like this
unstar this property grouped question UIN 7366 more like this
star this property question first answered
less than 2015-07-20T14:46:34.793Zmore like thismore than 2015-07-20T14:46:34.793Z
star this property answering member
3996
star this property label Biography information for Andrew Jones more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
390466
unstar this property registered interest false remove filter
star this property date less than 2015-07-15more like thismore than 2015-07-15
star this property answering body
Department for Transport more like this
star this property answering dept id 27 more like this
star this property answering dept short name Transport more like this
star this property answering dept sort name Transport more like this
star this property hansard heading Large Goods Vehicles more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Transport, if his Department will bring forward legislative proposals to require heavy goods vehicles satellite navigation system providers to remove weight-restricted roads from their routes. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham more like this
star this property uin 7366 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
star this property answer text <p>All road users benefit from clear directions, including HGV drivers. It is clearly not in the interests of HGV drivers to rely upon inaccurate information, which may make them late or even involve them in accidents. Nevertheless, we believe that legislation would be a costly, bureaucratic and inappropriate way of dealing with the problem. Instead we have made significant efforts to link together freight associations, local authorities and satnav companies to ensure that HGV drivers are aware of the issue and have the latest information available to them.</p><p> </p><p> </p><p> </p><p>Councils already have the means to set height and weight restrictions for roads, which are enforced by the police, and HGV satnav devices increasingly include up-to-date routing information that takes account of such restrictions.</p><p> </p><p> </p><p> </p><p>Decisions on all aspects of traffic management policy are the responsibility of local traffic authorities, and how they and the police enforce this once they are in place it is a matter for them. We believe the necessary enforcement powers are available for this.</p><p> </p>
star this property answering member constituency Harrogate and Knaresborough more like this
star this property answering member printed Andrew Jones more like this
unstar this property grouped question UIN 7365 more like this
star this property question first answered
less than 2015-07-20T14:46:34.697Zmore like thismore than 2015-07-20T14:46:34.697Z
star this property answering member
3996
star this property label Biography information for Andrew Jones more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
1327743
unstar this property registered interest false remove filter
star this property date less than 2021-05-25more like thismore than 2021-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Antibiotics: Side Effects more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, how many and what proportion of patients who are prescribed fluoroquinolone antibiotics suffer adverse reactions in the form of (a) tendon injury, (b) mitochondrial dysfunction and (c) oxidative stress. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 7154 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2021-06-09more like thismore than 2021-06-09
star this property answer text <p>The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.</p><p> </p><p>The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.</p><p> </p><table><tbody><tr><td><p>Reaction</p></td><td><p>Number of reports</p></td></tr><tr><td><p>Tendon disorders*</p></td><td><p>1,381</p></td></tr><tr><td><p>mitochondrial cytopathy, mitochondrial toxicity, mitochondrial myopathy acquired</p></td><td><p>1</p></td></tr><tr><td><p>Oxidative stress</p></td><td><p>2**</p></td></tr></tbody></table><p> </p><p>Source: MHRA Sentinel database for Adverse Drug Reactions.</p><p> </p><p>Notes:</p><p> </p><p>*Tendon disorders includes 21 different relevant reaction terms.</p><p>**These reports are duplicates and have been subsequently merged on the database.</p><p> </p><p>The frequency of tendonitis range from 1 in 100 to less than 1 in 10,000, depending on the specific fluoroquinolone medicine. For the products that provide an estimate of the frequency of tendon rupture, this is listed as less than 1 in 10,000. Mitochondrial dysfunction and oxidative stress are among the possible mechanisms that might lead to tendon injury or other ADRs caused by fluoroquinolones, but this association is not fully understood and mitochondrial dysfunction and oxidative stress are not listed as ADRs in the product information for fluoroquinolones.</p><p> </p><p>The MHRA continues to review information about the safety of all medicines, including fluoroquinolones, and will take appropriate regulatory action as appropriate on the basis of new safety information. Serious side effects of fluoroquinolone antibiotics can be varied, potentially affecting several different parts of the body. An assessment of the potential merits of fluoroquinolone toxicity as a clinical diagnosis in response to tendon injury, mitochondrial dysfunction or oxidative stress has not been made.</p>
star this property answering member constituency Mid Bedfordshire more like this
star this property answering member printed Ms Nadine Dorries more like this
unstar this property grouped question UIN 7155 more like this
star this property question first answered
less than 2021-06-09T09:32:28.03Zmore like thismore than 2021-06-09T09:32:28.03Z
star this property answering member
1481
star this property label Biography information for Ms Nadine Dorries more like this
star this property previous answer version
4612
star this property answering member constituency Mid Bedfordshire more like this
star this property answering member printed Ms Nadine Dorries more like this
star this property answering member
1481
star this property label Biography information for Ms Nadine Dorries more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
1327744
unstar this property registered interest false remove filter
star this property date less than 2021-05-25more like thismore than 2021-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Antibiotics: Side Effects more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of establishing fluoroquinolone toxicity as a diagnosis in response to (a) tendon injury, (b) mitochondrial dysfunction and (c) oxidative stress attributed by some patients to the use of that drug. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 7155 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2021-06-09more like thismore than 2021-06-09
star this property answer text <p>The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.</p><p> </p><p>The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.</p><p> </p><table><tbody><tr><td><p>Reaction</p></td><td><p>Number of reports</p></td></tr><tr><td><p>Tendon disorders*</p></td><td><p>1,381</p></td></tr><tr><td><p>mitochondrial cytopathy, mitochondrial toxicity, mitochondrial myopathy acquired</p></td><td><p>1</p></td></tr><tr><td><p>Oxidative stress</p></td><td><p>2**</p></td></tr></tbody></table><p> </p><p>Source: MHRA Sentinel database for Adverse Drug Reactions.</p><p> </p><p>Notes:</p><p> </p><p>*Tendon disorders includes 21 different relevant reaction terms.</p><p>**These reports are duplicates and have been subsequently merged on the database.</p><p> </p><p>The frequency of tendonitis range from 1 in 100 to less than 1 in 10,000, depending on the specific fluoroquinolone medicine. For the products that provide an estimate of the frequency of tendon rupture, this is listed as less than 1 in 10,000. Mitochondrial dysfunction and oxidative stress are among the possible mechanisms that might lead to tendon injury or other ADRs caused by fluoroquinolones, but this association is not fully understood and mitochondrial dysfunction and oxidative stress are not listed as ADRs in the product information for fluoroquinolones.</p><p> </p><p>The MHRA continues to review information about the safety of all medicines, including fluoroquinolones, and will take appropriate regulatory action as appropriate on the basis of new safety information. Serious side effects of fluoroquinolone antibiotics can be varied, potentially affecting several different parts of the body. An assessment of the potential merits of fluoroquinolone toxicity as a clinical diagnosis in response to tendon injury, mitochondrial dysfunction or oxidative stress has not been made.</p>
star this property answering member constituency Mid Bedfordshire more like this
star this property answering member printed Ms Nadine Dorries more like this
unstar this property grouped question UIN 7154 more like this
star this property question first answered
less than 2021-06-09T09:32:28.107Zmore like thismore than 2021-06-09T09:32:28.107Z
star this property answering member
1481
star this property label Biography information for Ms Nadine Dorries more like this
star this property previous answer version
4615
star this property answering member constituency Faversham and Mid Kent more like this
star this property answering member printed Helen Whately more like this
star this property answering member 4527
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
1327551
unstar this property registered interest false remove filter
star this property date less than 2021-05-24more like thismore than 2021-05-24
star this property answering body
Foreign, Commonwealth and Development Office more like this
star this property answering dept id 208 more like this
star this property answering dept short name Foreign, Commonwealth and Development Office more like this
star this property answering dept sort name Foreign, Commonwealth and Development Office more like this
star this property hansard heading Tigray: Development Aid more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, how much Official Development Assistance the UK has allocated for the current financial year to help victims of rape and torture in Tigray. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 6265 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2021-05-27more like thismore than 2021-05-27
star this property answer text <p>The UK provided £241 million of bilateral Official Development Assistance in 2020/21. The UK made the decision in November 2020 to pause financial aid payments to the Government of Ethiopia destined for Tigray but we continue to provide support to people in Tigray via UN and NGO partners. £22 million has been allocated to the humanitarian response in Tigray to support those in need.</p><p>UK-funded partners such as UN Office for the Coordination of Humanitarian Affairs (OCHA), UN Children's Fund (UNICEF), UN's World Food Programme (WFP) and International Committee of the Red Cross are providing food, shelter, water and healthcare in challenging circumstances. The UK is in the process of allocating budgets for programmes this financial year. As we do this, we will continue to review and adapt to the context.</p><p>The UK is also supporting civil society partners in Tigray to deliver gender-based violence and sexual and reproductive health response, which includes helping rape survivors. Final budgets are under review but we are also planning to support the documentation and investigation of such crimes.</p>
star this property answering member constituency Rochford and Southend East more like this
star this property answering member printed James Duddridge more like this
unstar this property grouped question UIN 6267 more like this
star this property question first answered
less than 2021-05-27T15:44:59.467Zmore like thismore than 2021-05-27T15:44:59.467Z
star this property answering member
1559
star this property label Biography information for Sir James Duddridge more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
1327553
unstar this property registered interest false remove filter
star this property date less than 2021-05-24more like thismore than 2021-05-24
star this property answering body
Foreign, Commonwealth and Development Office more like this
star this property answering dept id 208 more like this
star this property answering dept short name Foreign, Commonwealth and Development Office more like this
star this property answering dept sort name Foreign, Commonwealth and Development Office more like this
star this property hansard heading Tigray: Development Aid more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, how much Official Development Assistance has been allocated to programmes based in the Tigray; and for what purposes that funding has been allocated. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Mrs Pauline Latham more like this
star this property uin 6267 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2021-05-27more like thismore than 2021-05-27
star this property answer text <p>The UK provided £241 million of bilateral Official Development Assistance in 2020/21. The UK made the decision in November 2020 to pause financial aid payments to the Government of Ethiopia destined for Tigray but we continue to provide support to people in Tigray via UN and NGO partners. £22 million has been allocated to the humanitarian response in Tigray to support those in need.</p><p>UK-funded partners such as UN Office for the Coordination of Humanitarian Affairs (OCHA), UN Children's Fund (UNICEF), UN's World Food Programme (WFP) and International Committee of the Red Cross are providing food, shelter, water and healthcare in challenging circumstances. The UK is in the process of allocating budgets for programmes this financial year. As we do this, we will continue to review and adapt to the context.</p><p>The UK is also supporting civil society partners in Tigray to deliver gender-based violence and sexual and reproductive health response, which includes helping rape survivors. Final budgets are under review but we are also planning to support the documentation and investigation of such crimes.</p>
star this property answering member constituency Rochford and Southend East more like this
star this property answering member printed James Duddridge more like this
unstar this property grouped question UIN 6265 more like this
star this property question first answered
less than 2021-05-27T15:44:59.543Zmore like thismore than 2021-05-27T15:44:59.543Z
star this property answering member
1559
star this property label Biography information for Sir James Duddridge more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
657124
unstar this property registered interest false remove filter
star this property date less than 2016-12-12more like thismore than 2016-12-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Skin Cancer: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what restrictions have been placed on patients accessing treatments for advanced (stage 4) melanoma by (a) NHS England, (b) his Department and (c) NICE. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham more like this
star this property uin 57212 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2016-12-20more like thismore than 2016-12-20
star this property answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p>
star this property answering member constituency Oxford West and Abingdon more like this
star this property answering member printed Nicola Blackwood more like this
unstar this property grouped question UIN 57299 more like this
star this property question first answered
less than 2016-12-20T10:28:45.483Zmore like thismore than 2016-12-20T10:28:45.483Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
657941
unstar this property registered interest false remove filter
star this property date less than 2016-12-13more like thismore than 2016-12-13
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Access more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what steps his Department is taking to prevent NHS England from imposing restrictions on patients' access to NICE-approved treatments for melanoma and other conditions; and if he will make a statement. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham more like this
star this property uin 57299 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2016-12-20more like thismore than 2016-12-20
star this property answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p>
star this property answering member constituency Oxford West and Abingdon more like this
star this property answering member printed Nicola Blackwood more like this
unstar this property grouped question UIN 57212 more like this
star this property question first answered
less than 2016-12-20T10:28:45.56Zmore like thismore than 2016-12-20T10:28:45.56Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this